Activity of imipenem/relebactam and comparators against gram-negative pathogens from patients with bloodstream infections in the United States and Canada - SMART 2018-2019.
Sign Up to like & getrecommendations! Published in 2021 at "Diagnostic microbiology and infectious disease"
DOI: 10.1016/j.diagmicrobio.2021.115421
Abstract: Bloodstream infections (BSI) are often caused by drug-resistant pathogens, and novel antimicrobials are needed. We examined the activity of imipenem/relebactam against BSI pathogens from US and Canada: >99% of non-Morganellaceae Enterobacterales, including 100% of MDR… read more here.
Keywords: bloodstream infections; relebactam; imipenem relebactam; activity imipenem ... See more keywords
In Vitro Antibacterial Activity of Imipenem/Relebactam against Clinical Isolates in Japan
Sign Up to like & getrecommendations! Published in 2022 at "Microbiology Spectrum"
DOI: 10.1128/spectrum.02235-21
Abstract: Carbapenem-resistant Enterobacterales and carbapenem-resistant Pseudomonas aeruginosa strains pose a global threat. Antibacterial activity of imipenem/relebactam (IMR) against clinical isolates of these bacteria from several global regions has been shown; however, as yet there are no… read more here.
Keywords: antibacterial activity; carbapenem resistant; imipenem relebactam; activity imipenem ... See more keywords